Company Overview
| Stock Name | Ethk Labs Inc. |
|---|---|
| Stock Code | 01931 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為中國體外診斷(IVD)產品分銷商,主要透過達承於上海分銷IVD分析儀、試劑及其他耗材,並從事自有品牌IVD產品的研究、開發、生產及銷售。 |
| Listing Date | 2019-07-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 上海市浦東新區張江高科技園區畢昇路299弄第一上海中心6號樓602室 |
| Business Address (Hong Kong) | 香港沙田安平街8號偉達中心1703室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.ivdholding.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 3.07 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-06-29 to 2019-07-05 |
| Global Offering Shares | 333,400,000 shares |
| HK Public Offer Shares (Initial) | 33,340,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 300,060,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,333,400,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,023,538,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.29B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +627% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 年內溢利約人民幣99.5百萬元 |
| Period-End Cash Balance | 人民幣115.4百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 1,380,870 | 1,595,626 | 1,852,514 |
| Cost of sales | -1,050,586 | -1,235,209 | -1,484,574 |
| Gross profit | 330,284 | 360,417 | 367,940 |
| Other income and gains, net | 9,076 | 5,891 | 27,273 |
| Selling and distribution expenses | -103,838 | -80,178 | -80,971 |
| Administrative expenses | -29,710 | -32,821 | -37,495 |
| Net finance costs | -7,254 | -7,732 | -6,633 |
| Share of associates and JVs | -462 | -259 | -344 |
| Profit before tax | 193,076 | 240,798 | 265,803 |
| Income tax expense | -54,252 | -66,718 | -73,642 |
| Profit for the year | 138,824 | 174,080 | 192,161 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 156,790 | 220,802 | 163,678 |
| Trade and bills receivables | 107,052 | 137,828 | 190,908 |
| Inventories | 422,796 | 473,590 | 525,823 |
| Total current assets | 890,265 | 1,069,239 | 1,085,185 |
| Total current liabilities | 397,538 | 424,384 | 274,483 |
| Total equity | 492,116 | 637,374 | 792,382 |
| Interest-bearing borrowings | 130,000 | 100,000 | 40,000 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Net cash from operating activities | -13,426 | 68,514 | 66,733 |
| Net cash from investing activities | 3,063 | 9,028 | 9,059 |
| Net cash from financing activities | 27,855 | -12,115 | -133,568 |
| Net increase in cash | 17,492 | 65,427 | -57,776 |
| Depreciation of PP&E | 8,492 | 7,514 | 7,064 |
| Purchase of PP&E | -1,773 | -351 | -721 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.07 |
|---|---|
| First Day Open | HK$ 2.81 |
| First Day Change | -71.34% |
| First Day Volume | 38324000.0 |
| First Day Turnover | 118896000.0 |
| Use of Proceeds | 1、約49.6%或461.7百萬港元將用于結清收購威士達60%股權的現金代價之未償還結余;
2、約32.9%或306.8百萬港元將用于根據股東協議向本公司及威士達現有股東支付部分特別股息;
3、約6.8%或63.7百萬港元將主要用于擴大分銷業務項下的客戶群;
4、約3.5%或32.5百萬港元將用于繼續研發我們的自有品牌產品;
5、約2.6%或24.0百萬港元將用于擴展我們的分銷業務及改善我們的分銷價值鏈;
6、約4.6%或43.0百萬港元將用于營運資金及一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (4)
Joint Lead Managers (4)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 何鞠誠 | — |
| Company Secretary | 林惠茵 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 何鞠誠、梁景新及林賢雅連同彼等各自全資投資控股公司合共持有約34.78%股份;新華醫療透過全資附屬公司華佗持有約33.27%股份。 |
|---|




